Xiaoli Yu

Papers

Total Citations

129

H-Index

About

Xiaoli Yu is a pioneering researcher in synthetic biology and bacterial therapeutics, with a focus on engineering probiotic bacteria for targeted cancer therapy. Her most cited work, "Bioengineered *Escherichia coli* Nissle 1917 for tumour‐targeting therapy" (2019, 129 citations), introduces a groundbreaking approach to reprogramming non-pathogenic bacteria into microscopic "living robotic factories." By employing a top-down bioengineering strategy, Yu demonstrates how *E. coli* Nissle 1917 can be precisely modified to produce and deliver anticancer agents directly to tumor sites, offering a safer and more controllable alternative to traditional bacterial vectors like *Salmonella typhimurium*. This work has significantly advanced the field of bacterial vector-based drug delivery, highlighting the potential of probiotics as versatile, biocompatible platforms for precision medicine. Yu’s contributions have garnered substantial attention, with her research cited over 129 times, underscoring its impact on the development of next-generation cancer therapies. Her innovative integration of synthetic biology and oncology continues to inspire new avenues for harnessing living systems in the fight against disease.